ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Interestingly, p63 and p73 are mainly regulated at the transcriptional level, whereas p53 is essentially controlled by translational and post- translational mechanisms (enhanced mRNA translation (Reich et al., 1983) and control of protein stability (Haupt et al., 1997; Kubbutat et al., 1997)).”
Backgroundp63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,225
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
p63 is a p53 homologue required for limb and epidermal morphogenesis
Mills, A. A., Zheng, B., Wang, X.-J., Vogel, H., Roop, D. R., & Bradley, A. (1999) · Nature · doi:10.1038/19531 · Cited by 1,988
At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells
Kozak, M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90418-9 · Cited by 1,182 · cited 1×
“Codon 40 (position 118) lies within a well-defined sequence environment matching Kozak’s consensus criteria (Figure 2c) (Kozak, 1987).”
BackgroundYang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., et al. (2000) · Nature · doi:10.1038/35003607 · Cited by 990
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Control of cell cycle progression by c-Jun is p53 dependent
Schreiber, M., Kolbus, A., Piu, F., Szabowski, A., Mohle-Steinlein, U., Tian, J., Karin, M., Angel, P., & Wagner, E. F. (1999) · Genes & Development · doi:10.1101/gad.13.5.607 · Cited by 574
Cited by
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
“40p53 can also act, after transfection, in a dominant-negative manner toward wild-type p53, inhibiting both p53 transcriptional activity and p53-mediated apoptosis (Courtois et al. 2002; Ghosh et al. 2004).”
BackgroundInfluentialModulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586
“Thus, the p53 homologs in lower organisms more closely resemble a short form of p53 (DeltaN-p53) that was recently identified in mammalian cell lines and in normal cells from several different tissues (Courtois et al. 2002; Yin et al. 2002).”
BackgroundResultInfluentialTherapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
p63 and p73: Roles in Development and Tumor Formation
Moll, U. M., & Slade, N. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.371.2.7 · Cited by 486
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective
Bourdon, J.-C., Surget, S., & Khoury, M. P. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s53876 · Cited by 382
The Carboxy-Terminal Neh3 Domain of Nrf2 Is Required for Transcriptional Activation
Nioi, P., Nguyen, T., Sherratt, P. J., & Pickett, C. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10895-10906.2005 · Cited by 381
p53 — a Jack of all trades but master of none
Junttila, M. R., & Evan, G. I. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2728 · Cited by 345
Alternative splicing in cancer: implications for biology and therapy
Chen, J., & Weiss, W. A. (2015) · Oncogene · doi:10.1038/onc.2013.570 · Cited by 304
Detecting p53 Isoforms at Protein Level
Marcel, V., Khoury, M. P., Fernandes, K., Diot, A., Lane, D. P., & Bourdon, J.-C. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-236-0_2 · Cited by 22
Metadata
- Authors
- Courtois, S., Verhaegh, G., North, S., Luciani, M.-G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P.
- Venue
- Oncogene
- Published
- 2002-10-02
- Volume
- 21
- Issue
- 44
- Pages
- 6722-6728
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2063589273
- Cited by
- 263
- References
- 34
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.